Avadel announces preliminary 2024 results and 2025 commercial priorities to accelerate the lumryz launch

-- approximately $50.0 million of net revenue from sales of lumryz™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on lumryz as of december 31, 2024, including 600 patients that initiated therapy in the fourth quarter --
AVDL Ratings Summary
AVDL Quant Ranking